<DOC>
	<DOCNO>NCT00382408</DOCNO>
	<brief_summary>This multicenter , double-blind , randomize , placebo-controlled study evaluate safety efficacy oral DR-5001 reduce attack rate febrile acute respiratory disease cause type-4 type-7 adenovirus well determine immunogenicity .</brief_summary>
	<brief_title>A Clinical Trial Evaluate Safety , Efficacy , Immunogenicity DR-5001</brief_title>
	<detailed_description>The study conduct two site include minimum 4 visit . The overall study duration participant approximately 8 week . Study participant undergo acute respiratory disease evaluation include throat swab blood draw . Each participant also contact six month follow-up information .</detailed_description>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Military recruit train Male female ; female , must nonchildbearing potential document negative pregnancy test &lt; /= 72 hour prior study medication administration agree become pregnant Female nursing infant planning nursing study Immunosuppressed reason , include past ( within last 6 month ) current treatment immunosuppressive therapy Known allergy component vaccine and/or placebo tablet Immunocompromised sexual partner immunocompromised individual home</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Acute respiratory disease prevention</keyword>
	<keyword>Adenovirus</keyword>
</DOC>